Compare EZRA & VIVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EZRA | VIVS |
|---|---|---|
| Founded | 2013 | 2007 |
| Country | United States | United States |
| Employees | 40 | 9 |
| Industry | Specialty Insurers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1M | 4.9M |
| IPO Year | N/A | N/A |
| Metric | EZRA | VIVS |
|---|---|---|
| Price | $0.17 | $1.40 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 1.5M | 53.4K |
| Earning Date | 05-14-2026 | 06-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $42.38 |
| Revenue Next Year | N/A | $15.42 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.15 | $1.25 |
| 52 Week High | $0.39 | $5.30 |
| Indicator | EZRA | VIVS |
|---|---|---|
| Relative Strength Index (RSI) | 40.14 | 38.12 |
| Support Level | $0.17 | $1.25 |
| Resistance Level | $0.23 | $2.21 |
| Average True Range (ATR) | 0.02 | 0.14 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 8.22 | 7.55 |
Reliance Global Group Inc operates as a holding company that acquires, owns, and actively manages insurance and technology-focused businesses. The company focuses on growing by pursuing acquisition strategies initially, and focuses on wholesale and retail insurance agencies. Its primary move is to identify specific risks to reward arbitrage opportunities and develop these on a national platform, thereby increasing revenues and returns, and then identify and acquire undervalued wholesale and retail insurance agencies with operations in growing or underserved segments, expand and optimize their operations. The Company operates as a single operating segment, the Insurance Segment, earning its revenues from insurance commissions.
VivoSim Labs Inc formerly, Organovo Holdings Inc is a biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD), including ulcerative colitis (UC), based on demonstration of clinical promise in three-dimensional (3D) human tissues as well as preclinical data. FXR is a mediator of gastrointestinal and liver diseases. It is now offering liver toxicology predictive screening and research services as well as working on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at all stages of drug development.